Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL11120034 | 1.00 | OPRM1 (0.46) | OPRM1SPHK1LMNATP53DNM1 | |
| Iodide SCHEMBL1502936 | 1.00 | OPRM1 (0.46) | OPRM1SPHK1LMNATP53DNM1 | |
| Iodide SCHEMBL10486489 | 1.00 | OPRM1 (0.46) | OPRM1SPHK1LMNATP53DNM1 | |
| Iodide SCHEMBL5137819 | 1.00 | OPRM1 (0.46) | OPRM1SPHK1LMNATP53DNM1 | |
| Iodide SCHEMBL5087082 | 1.00 | OPRM1 (0.46) | OPRM1SPHK1LMNATP53DNM1 | |
| Iodide SCHEMBL23275376 | 1.00 | OPRM1 (0.46) | OPRM1SPHK1LMNATP53DNM1 | |
| Iodide SCHEMBL5092090 | 1.00 | OPRM1 (0.46) | OPRM1SPHK1LMNATP53DNM1 | |
| Iodide SCHEMBL28233718 | 0.98 | OPRM1 (0.44) | OPRM1SPHK1LMNATP53DNM1 | |
| SCHEMBL37786 | 0.98 | OPRM1 (0.48) | OPRM1SPHK1LMNATP53DNM1 | |
| SCHEMBL17257510 | 0.98 | OPRM1 (0.48) | OPRM1SPHK1LMNATP53DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224458-A1 | PREPARATION OF METHIONINE OR SELENOMETHIONINE FROM HOMOSERINE VIA A 4-SUBSTITUTED 2-AMINOBUTANOIC ACID INTERMEDIATE | NOVUS INTERNATIONAL INC. (US) | 2011-09-15 | — | — | US | claimed |
| CN-108440379-B | Method for synthesizing nitrogen-containing heterocyclic compound by double amination of olefin in water phase | 安徽德信佳生物医药有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-109776381-B | Preparation method of spiro indolone compound in aqueous phase | 华中科技大学 | 2020-07-24 | — | — | CN | disclosed |
| US-8742170-B2 | Preparation of methionine or selenomethionine from homoserine via a 4-substituted 2-aminobutanoic acid intermediate | NOVUS INTERNATIONAL, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20110224458-A1 | PREPARATION OF METHIONINE OR SELENOMETHIONINE FROM HOMOSERINE VIA A 4-SUBSTITUTED 2-AMINOBUTANOIC ACID INTERMEDIATE | NOVUS INTERNATIONAL INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010118274-A1 | PREPARATION OF 6-KETO, 3-ALKOXY MORPHINANS | MALLINCKRODT INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261906-A1 | Preparation of 6-Keto, 3-Alkoxy Morphinans | MALLINCKRODT INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-6760989-B2 | Decorative badge and method of making | DELPHI TECHNOLOGIES, INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030221347-A1 | Decorative badge and method of making | AUTOLIV DEVELOPMENT AB (SE) | 2003-12-04 | — | — | US | disclosed |
| US-4401499-A | LAMINATION | SUMITOMO BAKELITE COMPANY LIMITED (JP) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261906-A1 | Preparation of 6-Keto, 3-Alkoxy Morphinans | FASN, CYP2D6, CYP2B6 | OPRM1 126/4885SPHK1 554/4885LMNA 668/4885 |
| US-20110224458-A1 | PREPARATION OF METHIONINE OR SELENOMETHIONINE FROM HOMOSERINE VIA A 4-SUBSTITUTED 2-AMINOBUTANOIC ACID INTERMEDIATE | MTR, CBS, ABAT | OPRM1 3698/4885SPHK1 2668/4885LMNA 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.